Drugs / BB-101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03888053 Comparator | Mar 2018 → Dec 2021 | ulcer of lower limbs | Blue Blood Biotech Corp. | Completed | No outcome recorded |
| Phase 2 | NCT06383013 Comparator | May 2024 → Dec 2027 expected | ulcer of lower limbs | Blue Blood Biotech Corp. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06383013 ↗ |
| Known as | rhNEGF | “Topical BB-101 (rhNEGF)” NCT03888053 ↗ |
| Route | Topical | “Topical BB-101 (rhNEGF)” NCT03888053 ↗ |